<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03855293</url>
  </required_header>
  <id_info>
    <org_study_id>Rhexis Protection Shield</org_study_id>
    <nct_id>NCT03855293</nct_id>
  </id_info>
  <brief_title>Protecting the Corneal Endothelium During Cataract Surgery Using the Anterior Capsule</brief_title>
  <official_title>Protecting the Corneal Endothelium During Cataract Surgery Using the Anterior Capsule: a Prospective Randomised Double-masked Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Prim. Prof. Dr. Oliver Findl, MBA</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vienna Institute for Research in Ocular Surgery</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Cataract surgery is one of the most frequently performed surgical procedures worldwide. Since
      the introduction of phacoemulsification to remove the cataractous lens, risk and complication
      rates of cataract surgery decreased significantly.

      The phacoemulsification technique utilizes a high-intensity ultrasound energy for the
      fragmentation and emulsification of the lens. One of the main complications during
      phacoemulsification, is damaging of the endothelium due to contact with lens fragments of the
      nucleus following turbulent flow of irrigating solution, resulting in corneal damage,
      inflammation of the endothelium and corneal edema.

      In this study we want to evaluate the effect of the anterior capsule, gained by capsular
      rhexis, as a corneal shield during phacoemulsification on the corneal endothelium.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 2, 2016</start_date>
  <completion_date type="Actual">April 5, 2018</completion_date>
  <primary_completion_date type="Actual">April 1, 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>endothelium cell loss</measure>
    <time_frame>1 year</time_frame>
    <description>Comparison of the lost endothelium cells in both groups</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>central corneal thickness</measure>
    <time_frame>1 year</time_frame>
    <description>Comparison of corneal thickness between both groups</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">70</enrollment>
  <condition>Endothelial Cell Loss, Corneal</condition>
  <arm_group>
    <arm_group_label>Study group</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>rhexis protection shield</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>regular surgery</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Rhexis protection shield</intervention_name>
    <description>In the study group the anterior capsule will be used as a protection shield during pacoemulsifikation and removed after the phacoemulsifikation</description>
    <arm_group_label>Study group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Cataract

          -  Age 21 and older

          -  Written informed consent prior to surgery

          -  Moderate to severe nuclear or mixed cataract

        Exclusion Criteria:

          -  Corneal pathologies

          -  Pregnancy

          -  Patients with an increased surgical risk (i.e. patients with pseudoexfoliation
             syndrome, patients with the potential risk of intra-operative floppy iris syndrome)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>February 2019</verification_date>
  <study_first_submitted>February 24, 2019</study_first_submitted>
  <study_first_submitted_qc>February 24, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">February 26, 2019</study_first_posted>
  <last_update_submitted>February 24, 2019</last_update_submitted>
  <last_update_submitted_qc>February 24, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">February 26, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Vienna Institute for Research in Ocular Surgery</investigator_affiliation>
    <investigator_full_name>Prim. Prof. Dr. Oliver Findl, MBA</investigator_full_name>
    <investigator_title>Prim. Prof. Dr.</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cataract</mesh_term>
    <mesh_term>Corneal Endothelial Cell Loss</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

